Literature DB >> 22529162

Investigating FGF-23 concentrations and its relationship with declining renal function in paediatric patients with pre-dialysis CKD Stages 3-5.

Manish D Sinha1, Charles Turner, R N Dalton, Pernille Rasmussen, Simon Waller, Caroline J Booth, David J Goldsmith.   

Abstract

BACKGROUND: The aims of our study were to investigate (i) the prevalence of elevated fibroblast growth factor-23 (FGF-23), (ii) the relationship between FGF-23 concentrations and level of renal dysfunction and (iii) the main determinants of elevation of FGF-23 concentration in children with pre-dialysis chronic kidney disease (CKD) Stages 3-5.
METHODS: In this single-centre prospective observational study, 71 children with pre-dialysis CKD Stages 3-5, aged 11.9 ± 3.1 years, had FGF-23 levels measured. Anthropometry and routine laboratory investigations were measured.
RESULTS: Fourteen (19.7%) patients had normal FGF-23 concentrations defined as < 50 ng/L. FGF-23 [median (interquartile range)] concentrations were 78.7 (55.6-137.6) ng/L and following log transformation normalized data with log FGF-23 [mean (SD)] values of 1.96 ± 0.4 ng/L. Log FGF-23 concentrations had a negative reciprocal relationship with estimated glomerular filtration rate (eGFR) (P < 0.0001) and 1,25 vitamin D3 levels (P = 0.01) and a positive relationship with phosphate (P = 0.03) and percent fractional excretion of phosphate (P = 0.01) but not with log-intact parathyroid hormone (PTH) (P = 0.22). Multiple linear regression demonstrated a strong relationship between log FGF-23 and eGFR only.
CONCLUSIONS: Elevated FGF-23 concentrations were observed in the majority of a carefully managed cohort of children with non-dialysis CKD with a dominant effect on FGF-23 concentrations with glomerular filtration rate (GFR). These data allow the potential confounding effects of PTH and phosphate elevation with declining GFR to be removed, leaving a clearer picture of the FGF-23-GFR relationship.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22529162     DOI: 10.1093/ndt/gfs109

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  14 in total

Review 1.  Bone Disease in CKD in Children.

Authors:  Fernando Santos; Lucas Díaz-Anadón; Flor A Ordóñez; Dieter Haffner
Journal:  Calcif Tissue Int       Date:  2021-01-16       Impact factor: 4.333

2.  Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease.

Authors:  Manish D Sinha; Charles Turner; Caroline J Booth; Simon Waller; Pernille Rasmussen; David J A Goldsmith; John M Simpson
Journal:  Pediatr Nephrol       Date:  2015-05-15       Impact factor: 3.714

3.  FGF23 concentrations measured using "intact" assays similar but not interchangeable.

Authors:  Manish D Sinha; Charles Turner; David J Goldsmith
Journal:  Int Urol Nephrol       Date:  2013-05-07       Impact factor: 2.370

4.  Disordered FGF23 and mineral metabolism in children with CKD.

Authors:  Anthony A Portale; Myles Wolf; Harald Jüppner; Shari Messinger; Juhi Kumar; Katherine Wesseling-Perry; George J Schwartz; Susan L Furth; Bradley A Warady; Isidro B Salusky
Journal:  Clin J Am Soc Nephrol       Date:  2013-12-05       Impact factor: 8.237

5.  Factors associated with 1-year changes in serum fibroblast growth factor 23 levels in pediatric patients with chronic kidney disease.

Authors:  Natsumi Yamamura-Miyazaki; Toshimi Michigami; Keiichi Ozono; Katsusuke Yamamoto; Yukiko Hasuike
Journal:  Clin Exp Nephrol       Date:  2022-05-25       Impact factor: 2.617

6.  Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder?

Authors:  Andreja Figurek; Goce Spasovski
Journal:  Int Urol Nephrol       Date:  2018-07-20       Impact factor: 2.370

Review 7.  Bone disease in pediatric chronic kidney disease.

Authors:  Katherine Wesseling-Perry
Journal:  Pediatr Nephrol       Date:  2012-10-14       Impact factor: 3.714

8.  Longitudinal FGF23 and Klotho axis characterization in children treated with chronic peritoneal dialysis.

Authors:  Francisco J Cano; Michael Freundlich; Maria L Ceballos; Angelica P Rojo; Marta A Azocar; Iris O Delgado; Maria J Ibacache; Maria A Delucchi; Ana M Lillo; Carlos E Irarrázabal; Maria F Ugarte
Journal:  Clin Kidney J       Date:  2014-08-08

Review 9.  Immune dysfunction in uremia&#8212;an update.

Authors:  Gerald Cohen; Walter H Hörl
Journal:  Toxins (Basel)       Date:  2012-10-24       Impact factor: 4.546

Review 10.  Children's, parents' and other stakeholders' perspectives on early dietary self-management to delay disease progression of chronic disease in children: a protocol for a mixed studies systematic review with a narrative synthesis.

Authors:  Pearl Pugh; Pippa Hemingway; Martin Christian; Gina Higginbottom
Journal:  Syst Rev       Date:  2018-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.